Opioid use disorder

Last updated: September 09, 2025

Opioid use disorder

MSKD

MSKD

Bones of the vertebral column
Vessels and nerves of the vertebral column
Joints of the vertebral column
Muscles of the back
Anatomy of the vertebral canal
Anatomy clinical correlates: Vertebral canal
Anatomy clinical correlates: Spinal cord pathways
Anatomy clinical correlates: Bones, joints and muscles of the back
Anatomy of the suboccipital region
Ectoderm
Endoderm
Mesoderm
Development of the axial skeleton
Development of the nervous system
Central nervous system histology
Peripheral nervous system histology
Glucocorticoids
Opioid agonists, mixed agonist-antagonists and partial agonists
Non-steroidal anti-inflammatory drugs
Opioid antagonists
Carpal tunnel syndrome
Opioid use disorder
Spinal disc herniation
Degenerative disc disease
Back pain: Pathology review
Lower back pain: Clinical
Sympathetic nervous system
Parasympathetic nervous system
Introduction to the skeletal system
Introduction to the muscular system
Anatomical terminology
Anatomy of the pelvic girdle
Arteries and veins of the pelvis
Nerves and lymphatics of the pelvis
Bones of the lower limb
Fascia, vessels and nerves of the lower limb
Anatomy of the anterior and medial thigh
Muscles of the gluteal region and posterior thigh
Vessels and nerves of the gluteal region and posterior thigh
Anatomy of the popliteal fossa
Anatomy of the leg
Anatomy of the foot
Anatomy of the hip joint
Anatomy of the knee joint
Anatomy of the tibiofibular joints
Joints of the ankle and foot
Glycolysis
Glycogen metabolism
Gluconeogenesis
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Glycogen storage disease type I
Glycogen storage disease type III
Glycogen storage disease type V
Glycogen storage disease type IV
Glycogen storage disease type II (NORD)
Glycogen storage disorders: Pathology review
Cytoskeleton and intracellular motility
Osteogenesis imperfecta
Marfan syndrome
Ehlers-Danlos syndrome
Development of the limbs
Development of the muscular system
Achondroplasia
Myotonic dystrophy
Muscular dystrophy
Mitochondrial myopathy
Muscular dystrophies and mitochondrial myopathies: Pathology review
Bone histology
Skeletal muscle histology
Cartilage histology
Winged scapula
Klumpke paralysis
Erb-Duchenne palsy
Unhappy triad
Anterior cruciate ligament injury
Meniscus tear
Sprained ankle
Achilles tendon rupture
Spondylolysis
Spondylolisthesis
Pectus excavatum
Osteoporosis
Osteopetrosis
Osteomalacia and rickets
Lordosis, kyphosis, and scoliosis
Paget disease of bone
Osteoarthritis
Bursitis
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Bone disorders: Pathology review
Spina bifida
Osteoporosis medications
Skeletal system anatomy and physiology
Cartilage structure and growth
Bone remodeling and repair
Fibrous, cartilage, and synovial joints
Muscular system anatomy and physiology
Brachial plexus
Neuromuscular junction and motor unit
Sliding filament model of muscle contraction
Slow twitch and fast twitch muscle fibers
Muscle contraction
Muscle spindles and golgi tendon organs
Neuron action potential
Bones of the upper limb
Fascia, vessels and nerves of the upper limb
Anatomy of the brachial plexus
Anatomy of the pectoral and scapular regions
Anatomy of the arm
Muscles of the forearm
Vessels and nerves of the forearm
Muscles of the hand
Anatomy of the sternoclavicular and acromioclavicular joints
Anatomy of the glenohumeral joint
Anatomy of the elbow joint
Anatomy of the radioulnar joints
Joints of the wrist and hand
Anatomy of the axilla
Anatomy clinical correlates: Clavicle and shoulder
Anatomy clinical correlates: Axilla
Anatomy clinical correlates: Arm, elbow and forearm
Anatomy clinical correlates: Wrist and hand
Anatomy clinical correlates: Median, ulnar and radial nerves
Vitamin C deficiency
Nucleotide metabolism
Lesch-Nyhan syndrome
Adenosine deaminase deficiency
Orotic aciduria
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Staphylococcus epidermidis
Staphylococcus aureus
Streptococcus pyogenes (Group A Strep)
Streptococcus agalactiae (Group B Strep)
Streptococcus pneumoniae
Clostridium perfringens
Pseudomonas aeruginosa
Bacteroides fragilis
Neisseria gonorrhoeae
Mycobacterium tuberculosis (Tuberculosis)
Chlamydia trachomatis
Borrelia burgdorferi (Lyme disease)
Histoplasmosis
Candida
Miscellaneous cell wall synthesis inhibitors
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Osgood-Schlatter disease (traction apophysitis)
Rotator cuff tear
Dislocated shoulder
Radial head subluxation (Nursemaid elbow)
Thoracic outlet syndrome
Ulnar claw
Iliotibial band syndrome
Patellar tendon rupture
Patellofemoral pain syndrome
Sciatica
Compartment syndrome
Rhabdomyolysis
Cleidocranial dysplasia
Osteomyelitis
Bone tumors
Chondrosarcoma
Osteochondroma
Spondylosis
Spinal stenosis
Rheumatoid arthritis
Juvenile idiopathic arthritis
Gout
Calcium pyrophosphate deposition disease (pseudogout)
Psoriatic arthritis
Ankylosing spondylitis
Reactive arthritis
Spondylitis
Septic arthritis
Baker cyst
Polymyositis
Dermatomyositis
Inclusion body myopathy
Polymyalgia rheumatica
Fibromyalgia
Rhabdomyosarcoma
Sjogren syndrome
Raynaud phenomenon
Mixed connective tissue disease
Scleroderma
Systemic lupus erythematosus
Rheumatoid arthritis and osteoarthritis: Pathology review
Gout and pseudogout: Pathology review
Scleroderma: Pathology review
Sjogren syndrome: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Seronegative and septic arthritis: Pathology review
Myalgias and myositis: Pathology review
Neuromuscular junction disorders: Pathology review
Bone tumors: Pathology review
Benign hyperpigmented skin lesions: Clinical
Seborrhoeic dermatitis
Atopic dermatitis
Contact dermatitis
Blistering skin disorders: Clinical
Skin cancer: Clinical
Papulosquamous skin disorders: Clinical
Alopecia: Clinical
Hypopigmentation skin disorders: Clinical
Hair, skin and nails
Pediatric infectious rashes: Clinical
Eczematous rashes: Clinical
Skin cancer

Transcript

Watch video only

Worldwide, opioids are the most common cause of drug-related deaths.
The number of individuals using opioids has drastically increased over time, with an uptick in heroin use, and an even bigger uptick in prescription opioid use, and a large number of people using both. Because of the potential for opioid use disorder and overdose, opioids are regulated substances in many countries.

As a class, opioids share one thing in common—they bind to opioid receptors in the brain, spinal cord, and gastrointestinal tract. Some are endogenous, meaning that they are produced naturally by the body, like endorphins, which are named for “endogenous morphine” due to their similar effects on the body. But others are exogenous, meaning that they come from outside the body, like heroin and morphine, which come from the opium poppy—a flowering plant that oozes a milky white liquid—while others like fentanyl are synthesized in the laboratory.

To understand how opioids work, let’s zoom in on a region of the spinal cord that has opioid receptors. Normally, in the absence of endorphins, nociceptive fibers carry pain signals from the body to the dorsal, or posterior, horn of the spinal cord.

Here they release neurotransmitters,

like glutamate, substance P and calcitonin gene-related peptide. These neurotransmitters cause pain signals to be transmitted to the brain via ascending pain pathways.

Now, let’s say someone goes to play a rigorous game of badminton. Exercise releases endorphins which activate the three major opioid receptors located on neurons, called the mu, kappa, and delta receptors.

As endorphins or other opioids bind to these receptors on the presynaptic terminals of nociceptive fibers, they inhibit the opening of calcium channels, preventing calcium influx, and thereby blocking the release of pain-causing neurotransmitters like glutamate, substance P and calcitonin gene-related peptide. At the same time, endorphins also bind to postsynaptic neurons, opening potassium channels here, leading to hyperpolarization and decreased excitability of the neuron. These effects together reduce the transmission of pain signals to the brain.

If we move up to the brain’s reward pathway, made up of midbrain regions like the ventral tegmental area, nucleus accumbens, and prefrontal cortex, we find another important effect of opioids.

Here, inhibitory neurons normally release gamma-aminobutyric acid, or GABA, at the presynaptic terminal, which in turn inhibits postsynaptic dopaminergic neurons, leading to decreased dopamine release.

But, when there are endorphins or opioids in the area, they bind to the opioid receptors on these inhibitory GABAergic neurons, causing a decrease in GABA release. With less GABA around, there is less inhibition of dopaminergic neurons, leading to a flood of dopamine in the brain’s reward center. This increased dopamine leads to a calming sensation and feelings of pleasure or euphoria, also known as an emotional “high”.

Now remember, the purpose of the reward pathway is to train the brain to repeat activities that cause dopamine-mediated pleasure, so when opioids stimulate this reward pathway, the brain learns to do that behavior again and again.

With exogenous opioids, there are multiple routes to get the drug to the brain.

One way is by ingesting it; that route is the slowest. A faster route would be inhalation because the drug is rapidly absorbed through the lungs; this route is not routinely used medically and is more commonly encountered with substance misuse.

The fastest route is direct injection of the substance into the blood. Typically, the faster the exogenous opioid reaches the brain, the stronger the relationship between the behavior and the reward.

Over time, people can develop tolerance to a drug. Tolerance means that with repeated use, their response to the drug decreases. As a result, even when taking the medication exactly as prescribed, a higher dose may be needed to achieve the same effect as before.

At a cellular level, there are two main reasons for why this happens.

One reason is that opioid receptors become less sensitive to stimulation by a drug, and the other reason is that the neurons may remove opioid receptors from the cell membrane in a process called down-regulation, leaving fewer receptors available for binding. In either scenario, tolerance leads to the need for higher and higher doses of a drug, and often that tolerance remains for a long time even after tapering off the drug.

Alright, so now let’s say that you’re at rest, there aren’t any drugs or anything else stimulating your reward pathway. In this situation, your brain keeps your heart rate, blood pressure, and wakefulness in a normal state, called homeostasis.

Now, let’s say you finally get a text with exam results that you’ve been waiting weeks for. All of a sudden you may feel sweaty and flushed, your heart rate may jump a bit. You’re now above your normal level of homeostasis, because something has changed, right? But it doesn’t stay that way for long, and after the text message, your brain brings things back down to this baseline.

With repeated drug use, a few things start to happen.
Let’s say you take a drug at a specific time and setting, like 3:00 P.M. in the bedroom, every day.

If it’s a depressant, it makes everything go lower: heart rate, blood pressure, and wakefulness.

Your brain, being the smart brain that it is, will pick up on this pattern.

So, the next time it’s 3:00 P.M. in the bedroom, your brain preemptively increases heart rate, blood pressure and wakefulness, since it knows that when you take the drug, everything’s going to decrease again.

Now, let’s say 3:00 P.M. in the bedroom rolls around, but there’s no drug…

In that situation, the brain still increases everything, but the changes aren’t countered with the effects of the drug, and so the person can feel awful;

these are called withdrawal symptoms. These symptoms can persist to the point where a person may need drugs just to feel normal, and if that’s the case, they are considered to be dependent on that drug.

Now, on the flipside, let’s say that you use the drug in an unfamiliar setting, like at 11:00 P.M. at a party. Well in that situation, your body’s not ready for the drug and there’s no physiologic “counterbalance” to help offset the effect of the drug.

When that happens, it can lead to overdose, even on a “normal” dose that the person’s taking, and that’s oftentimes what happens.

The symptoms of opioid withdrawal include dysphoric mood, myalgias, sweating and shivering, yawning, nausea, vomiting, and diarrhea, rhinorrhea, pupillary dilation, and insomnia.

These symptoms can feel really awful, and often prompt people to use opioids again. This is called negative reinforcement, since you’re removing the drug, which causes withdrawal symptoms which reinforces more drug use to avoid those symptoms.

Key Takeaways

An opioid use disorder is a medical condition that is characterized by the compulsive use of opioids in spite of adverse consequences from continued use and the development of a withdrawal syndrome when opioid use stops. Opioids include substances such as morphine, heroin, codeine, oxycodone, hydrocodone, etc. The necessary descriptive characteristics of the medical diagnosis are preoccupation with a desire to obtain and take the drug and persistent drug-seeking behaviour. 

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine" McGraw Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "Pharmacological therapies for management of opium withdrawal" Cochrane Database of Systematic Reviews (2018)
  5. "An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program" Drug and Alcohol Dependence (2011)
  6. "Cellular basis of memory for addiction" Dialogues in Clinical Neuroscience (2013)